Ken Langone's Portfolio Shift

Ken Langone, chairman and president of Invemed Associates, says Eli Lilly stock is now pushing Home Depot for top billing in his portfolio.

“I think Lilly’s going to be a $2,000 stock in the next 3 or 4 years.”

Eli Lilly's Current Value

Eli Lilly traded at $1,153.83 as of 13:10 UTC on September 22, 2026, with a target of $2,000 in three to four years.

Home Depot's Current Value

Home Depot traded at $301.79 as of 13:10 UTC on September 22, 2026, down 25.33% over one year.

Langone's Portfolio Race

Langone said, 'Lilly’s come along pretty good, and it’s given Home Depot a real run. For whose first place in my portfolio.'

“Lilly’s come along pretty good, and it’s given Home Depot a real run. For whose first place in my portfolio.”

Eli Lilly's Growth Trajectory

Eli Lilly is up 54.41% over one year and 428.77% over five years, but down 8.09% over the past month.

Home Depot's Historical Performance

Home Depot is down 25.33% over one year, down 10.38% year to date, and up 2.01% over five years.

Langone's Research Focus

Langone credits John Lechleiter for building Eli Lilly’s research pipeline, saying the company spends $4 billion annually on R&D.

Eli Lilly's Market Capitalization

Eli Lilly’s market capitalization is $1,038,332,855,731, with a target of $2,000 per share in three to four years.